>
Switch to:

ORIC Pharmaceuticals ROA %

: -30.44% (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ORIC Pharmaceuticals's annualized Net Income for the quarter that ended in Jun. 2021 was $-84.04 Mil. ORIC Pharmaceuticals's average Total Assets over the quarter that ended in Jun. 2021 was $276.09 Mil. Therefore, ORIC Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2021 was -30.44%.

The historical rank and industry rank for ORIC Pharmaceuticals's ROA % or its related term are showing as below:

NAS:ORIC' s ROA % Range Over the Past 10 Years
Min: -45.71   Med: -38.18   Max: -36.7
Current: -36.7

-45.71
-36.7

During the past 3 years, ORIC Pharmaceuticals's highest ROA % was -36.70%. The lowest was -45.71%. And the median was -38.18%.

NAS:ORIC's ROA % is ranked lower than
99.99% of the 327 Companies
in the Biotechnology industry.

( Industry Median: -49.25 vs. NAS:ORIC: -36.70 )

ORIC Pharmaceuticals ROA % Historical Data

The historical data trend for ORIC Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20
ROA %
-45.71 -38.18 -37.50

ORIC Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.77 -51.98 -46.08 -22.66 -30.44

Competitive Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ORIC Pharmaceuticals ROA % Distribution

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's ROA % falls into.



ORIC Pharmaceuticals ROA % Calculation

ORIC Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2020 is calculated as:

ROA %=Net Income (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=-73.703/( (94.093+298.997)/ 2 )
=-73.703/196.545
=-37.50 %

ORIC Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2021 is calculated as:

ROA %=Net Income (Q: Jun. 2021 )/( (Total Assets (Q: Mar. 2021 )+Total Assets (Q: Jun. 2021 ))/ count )
=-84.036/( (283.96+268.227)/ 2 )
=-84.036/276.0935
=-30.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2021) net income data. ROA % is displayed in the 30-year financial page.


ORIC Pharmaceuticals  (NAS:ORIC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2021 )
=Net Income/Total Assets
=-84.036/276.0935
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-84.036 / 0)*(0 / 276.0935)
=Net Margin %*Asset Turnover
=N/A %*0
=-30.44 %

Note: The Net Income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ORIC Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

ORIC Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533.
Executives
Kunkel Lori Anne director C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Chacko Jacob director, officer: President and CEO C/O IGNYTA, INC. 11095 FLINTKOTE AVE., SUITE D SAN DIEGO CA 92121
Topspin Biotech Fund Ii, L.p. 10 percent owner 3 EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Lg Management, Llc 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Topspin Fund L.p. 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Heyman Richard A. director 5871 OBERLIN DRIVE, SUITE 150 SAN DIEGO CA 92121
Scheller Richard H director C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990
Guthart Leo 10 percent owner C/O APTUR GROUP INC 475 W TERRA COTTA AVE STE E CRYSTAL LAKE IL 60014
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Goeddel David V 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Svennilson Peter director, 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Gordon Carl L director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022

ORIC Pharmaceuticals Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)